Viking TherapeuticsVKTX
Market Cap: 7.31B
About: Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
Employees: 30
Fund manager confidence
Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)
589% more first-time investments, than exits
New positions opened: 193 | Existing positions closed: 28
550% more funds holding in top 10
Funds holding in top 10: 2 [Q4 2023] → 13 (+11) [Q1 2024]
361% more capital invested
Capital invested by funds: $1.42B [Q4 2023] → $6.54B (+$5.12B) [Q1 2024]
85% more funds holding
Funds holding: 195 [Q4 2023] → 360 (+165) [Q1 2024]
39% more call options, than puts
Call options by funds: $582M | Put options by funds: $420M
8% less repeat investments, than reductions
Existing positions increased: 77 | Existing positions reduced: 84
3.3% less ownership
Funds ownership: 76.32% [Q4 2023] → 73.01% (-3.3%) [Q1 2024]
Research analyst outlook
26 Wall Street Analysts provided 1 year price forecasts over the past 6 months
26 analyst ratings
Raymond James Steven Seedhouse | 79%upside $118 | Strong Buy Maintained | 25 Jul 2024 |
HC Wainwright & Co. Joseph Pantginis | 36%upside $90 | Buy Reiterated | 25 Jul 2024 |
Morgan Stanley Michael Ulz | 59%upside $105 | Overweight Initiated | 27 Jun 2024 |
HC Wainwright & Co. Joseph Pantginis | 36%upside $90 | Buy Reiterated | 24 Jun 2024 |
Truist Securities Joon Lee | 82%upside $120 | Buy Maintained | 17 Jun 2024 |
Financial journalist opinion
Based on 35 articles about VKTX published over the past 30 days